314 related articles for article (PubMed ID: 27631521)
1. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
[TBL] [Abstract][Full Text] [Related]
2. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
[TBL] [Abstract][Full Text] [Related]
3. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
Nagaria TS; Wang H; Chatterjee D; Wang H
Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
[TBL] [Abstract][Full Text] [Related]
4. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
Chatterjee D; Katz MH; Foo WC; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2017 Aug; 41(8):1097-1104. PubMed ID: 28614206
[TBL] [Abstract][Full Text] [Related]
6. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
[TBL] [Abstract][Full Text] [Related]
8. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
10. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
[TBL] [Abstract][Full Text] [Related]
11. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
12. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.
Fischer LK; Katz MH; Lee SM; Liu L; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Roland CL; Fleming JB; Estrella J; Rashid A; Wang H
Histopathology; 2016 Jan; 68(2):210-20. PubMed ID: 25945396
[TBL] [Abstract][Full Text] [Related]
13. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
14. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
20. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]